Verum Diagnostics Inc (Verum) discovers and commercializes biomarkers for the detection, prediction and treatment of clinically important conditions in women’s health and gastrointestinal disorders.
These include PROM (Premature Rupture of Membranes), preeclampsia, early and pregnancy loss.
The Amnio100 PROM test is our lead indication. Globally preterm birth is among the most frequent causes of death among neonates within the first month of life.
The Amnio100 has shown a significantly higher performance (100% specificity and 100% sensitivity) compared to existing PROM tests when tested on several thousand clinical samples. It will change the current PROM clinical management approach when introduced into the market.
Verum is open to discussing scientific, regulatory, and commercial strategic relationships to advance its programs.
Company’s Keywords:
biotech, biomarkers, pregnancy, gastrointestinal, appendicitis, prom, premature rupture of membranes, diagnostics, early pregnancy loss, preeclampsia, gastric cancer, gastric bleeding, ulcers, point of care, gastrointestinal bleeding
3
medical devices
Bootstrap Framework, Mobile Friendly, WordPress.org, Apache, Google Font API
2019
Your request has been submitted successfully.
Own or work here?